Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques

Not Applicable

Recruiting

• Conditions: Coronary Artery Disease
• Interventions: Device: Drug-eluting balloon treatment

• Registration Number: NCT04765956
• Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary

Rationale: Two-thirds of intracoronary thrombi causing acute coronary syndrome (ACS) result from rupture of lipid-rich plaques (LRP). After treatment of the culprit lesion in ACS patients, additional LRPs are found in approximately 50% of patients. Near infrared spectroscopy (NIRS) combined with intracoronary ultrasound (IVUS) can identify these vulnerable plaques during coronary angiography (CAG) and is able to assess plaque characteristics and the lipid-core burden index in a 4mm segment (LCBImm4). It is currently unknown whether treatment of LRPs leads to plaque stabilization, potentially reducing the number of subsequent ACS. We hypothesize that LRPs can be treated with balloons coated with an antiproliferative drug (i.e. drug-eluting balloons; DEB) to deliver selective pharmacotherapeutic treatment to halt the local atherosclerotic process and subsequently reduce the risk for atherosclerotic events.

Objectives: To determine the change in plaque characteristics of non-culprit LRPs, as measured with IVUS/NIRS, after treatment with DEB in patients with ACS.

Study design: Prospective single-arm clinical trial

Study population: Patients with non-ST-elevation acute coronary syndromes

Intervention: If a LRP is detected with IVUS/NIRS, it will be treated with DEB. In case multiple LRPs are detected, only one will be treated.

Main study endpoints: The difference in LCBImm4 between baseline and 9 months of plaques treated with DEB.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-19
• Study First Submitted: 2021-02-18
• Study First Submitted QC: 2021-02-22
• Study First Posted: 2021-02-23
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-31
• Last Update Posted: 2023-02-01
• Primary Completion: 2023-09-09
• Study Completion: 2023-09-09

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Patient has an acute coronary syndrome without ST-segment elevation on the ECG (NSTE-ACS), including non-ST-elevation myocardial infarction and unstable angina pectoris, defined according to the Fourth Universal Definition of Myocardial Infarction.
• An invasive revascularization strategy for NSTE-ACS with PCI is chosen.

Exclusion Criteria

• Angiographic exclusion criteria:

1. Previous coronary artery bypass-grafting;

2. Presence of a chronic total occlusion;

3. Too many (complex) coronary lesions requiring staged PCI procedure(s);

4. Procedural complication of the index PCI;

   • Clinical exclusion criteria:

5. Unstable patients (the presence of cardiogenic shock, need for intubation, need for inotropes);

6. Patients with ST-segment elevations on the ECG requiring immediate primary PCI;

7. Body weight > 250 kg;

8. Known renal insufficiency (estimated Glomerular Filtration Rate [eGFR] <30 mL/min/1.73m2 or subject on dialysis);

9. Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;

10. Presence of a comorbid condition with a life expectancy of less than one year;

11. Participation in another trial;

12. Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Drug-eluting balloon treatment	Drug-eluting balloon treatment	Drug-eluting balloon (DEB) treatment of lipid-rich plaque

Primary Outcome Measures

Name	Time	Method
LCBImm4 difference of DEB-treated LRPs	9 months	The difference in LCBImm4 between baseline and 9 months follow-up of lipid-rich plaques treated with drug-eluting balloon, as measured with near-infrared spectroscopy (NIRS).

Secondary Outcome Measures

Name	Time	Method
Rate of LRP lesion failure (defined as cardiac death, myocardial infarction, or ischemia-driven revascularization related to an identified non-culprit LRP lesion up to one-year follow-up);	1 year
Patient-oriented composite outcomes, defined as all-cause mortality, myocardial infarction, or any repeat revascularization up to one-year follow-up;	1 year
Additional IVUS + NIRS lesion characteristics: plaque volume	9 months
Additional IVUS + NIRS lesion characteristics: minimal lumen area	9 months
The change in lipid-core burden index in a 4 mm segment (LCBImm4) as measured with IVUS + NIRS from baseline to 9 month follow-up in identified additional LRPs that are not treated with DEB.	9 months
Rate of flow-limiting dissections necessitating bail-out stent implantation;	9 months
Rate of periprocedural myocardial infarction;	9 months

Trial Locations

Locations (1)

Amsterdam UMC, location AMC; 🇳🇱 Amsterdam, Netherlands